pfizer glp-1 news to discontinue danuglipron, its pill for obesity| STAT Pfizer, Innovent GLP-1 drugs move

Each study will also include a one-year extension allowing participants the opportunity to continue receiving treatment following completion of the primary dosing period, including patients receiving placebo during the initial portion of the trial

The primary outcome was all-cause mortality, and the secondary outcome was recurrence-free survival over a 10-year follow-up window

For laboratory use, it may be reconstituted with bacteriostatic water or another suitable solvent according to experimental protocols

If I can do it, so can YOU! Kelly, 45 At 23, my health was at serious risk, and I never thought Id lose the weight

Retatrutide has not it remains in clinical trials as of 2026 and has no approved label

Selank may interrupt that cycle at the enzymatic level, preserving what the body already produces